New FDA approval: Rocklatan.

What is Rocklatan?
It’s a drop used once daily to lower IOP and it’s a combo of two drugs, latanoprost and Rhopressa. Rhopressa was recently FDA approved at the end of 2017.

How does Rocklatan work?
Two main ways:
1. Increases uveoscleral outflow – latanoprost works here.
2. Increases outflow through the trabecular meshwork by inhibiting Rho Kinase (ROCK) – Rhopressa works here.

What are the side effects?
The most common ocular adverse reaction is conjunctival hyperemia (59%) but others include instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%).

How much more IOP lowering do we get with this combo drop?
According to their studies, 1 to 3mmHg more than monotherapy with either Rhopressa or latanoprost 0.005% alone. In their clinical trials, more than 60% of patients using Rocklatan achieved an IOP reduction of 30% or more.

When can we get it?
The company plans to launch in the second quarter of 2019. (via)

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

Related Articles

Latest Posts